t o r e
g . c o m
  Ticagrelor is recommended as a firstline antithrombotic agent in patients with acute coronary syndromes.
  Ticagrelor is a direct-acting and reversible P2Y12-adenosine diphosphate receptor antagonist.
  Inhibition of adenosine uptake results in increased adenosine tissue concentrations.
  The effect of ticagrelor on sinoatrial and AV nodes is believed to be mediated by an increased tissue concentration of adenosine.
  Sinus bradycardia
  Atrioventricular block
  Prolonged asystole
  QT interval prolongation
  Tex Heart Inst J 2019;46(3):203-206.
  Case Rep Cardiol 2019 Nov 7;2019:5984847. doi: 10.1155/2019/5984847. eCollection 2019
  HeartRhythm Case Rep 2018;4(11):527-529
  Case Rep Vasc Med. 2018 Apr 19;2018:9385017. doi: 10.1155/2018/9385017. eCollection 2018
  Ann Intern Med. 2018 Apr 17;168(8):602-603
  Cardiol Res 2017;8(3):123-127
  World J Clin Cases 2017;5(5):178-182
  Int J Cardiol 2016;214:21-22
  Int J Cardiol 2016;202:946-947
  Int J Cardiol 2015;182:379-380